EU may expand Tresiba indication

Share this article:

The EU's Committee for Medicinal Products for Human Use is endorsing expanded indications for Novo Nordisk's Type 2 diabetes medications Tresiba and Victoza.

The company said in a statement that if the European Medicines Agency agrees, new labels will indicate that the long-acting basal insulin Tresiba can be prescribed in tandem with a GLP-1 like Victoza, and that Victoza can be prescribed along with a long-acting basal insulin.

The potential expansion comes soon after the FDA put Tresiba at arm's-length in February, when it told the drugmaker to run cardiovascular safety tests before it would consider an approval.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.